iCAD Inc  

(Public, NASDAQ:ICAD)   Watch this stock  
Find more results for ICAD
5.79
-0.13 (-2.20%)
Real-time:   12:29PM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 5.77 - 5.85
52 week 1.75 - 6.90
Open 5.85
Vol / Avg. 10,750.00/39,801.00
Mkt cap 62.74M
P/E     -
Div/yield     -
EPS -0.73
Shares 10.84M
Beta 1.42
Inst. own 16%
Jul 29, 2013
Q2 2013 icad, Inc Earnings Release Add to calendar
May 20, 2013
icad, Inc Annual Shareholder Meeting
May 6, 2013
Q1 2013 icad, Inc Earnings Release
Apr 30, 2013
icad, Inc at Needham Healthcare Conference
Apr 30, 2013
Q1 2013 icad, Inc Earnings Conference Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '13) 2012
Net profit margin -9.17% -33.15%
Operating margin -4.14% -19.14%
EBITD margin - -9.26%
Return on average assets -4.93% -16.78%
Return on average equity -10.62% -29.42%
Employees 101 -
Carbon Disclosure Rating - -

Address

Suite 100, 98 Spit Brook Road
NASHUA, NH 03062-5734
United States - Map
+1-603-8825200 (Phone)
+1-603-8803843 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Discussion Group - Google Finance

Description

iCAD, Inc. (iCAD) is an advanced image analysis and workflow solutions that enable healthcare professionals to serve patients by identifying pathologies and pinpointing the most prevalent cancers earlier. iCAD offers a range of upgradeable Computer-Aided Detection (CAD) systems and workflow solutions for mammography, Magnetic Resonance Imaging (MRI) and Computed Tomography (CT). The Company's solutions enable radiologists to serve patients by identifying pathologies and pinpointing cancers. Its digital and MRI CAD products include advanced image analysis and workflow solutions in breast imaging (mammography), advanced image analysis and workflow solutions in MRI imaging - breast and prostate, and advanced image analysis and workflow solutions in CT Colonography. Its Film based products include products for converting mammography films to digital images. Its electronic brachytherapy products include electronic brachytherapy (Ebx) treatment for breast cancer.

Officers and directors

Lawrence Howard Chairman of the Board
Age: 60
Bio & Compensation  - Reuters
Kenneth Ferry President, Chief Executive Officer, Director
Age: 59
Bio & Compensation  - Reuters
Kevin C. Burns Chief Financial Officer, Executive Vice President - Finance, Treasurer, Secretary
Age: 42
Bio & Compensation  - Reuters
Stacey M. Stevens Senior Vice President - Marketing and Strategy
Age: 45
Bio & Compensation  - Reuters
Jonathan Go Senior Vice President - Research and Development
Age: 50
Bio & Compensation  - Reuters
Rachel Brem M.D. Independent Director
Age: 54
Bio & Compensation  - Reuters
Anthony F. Ecock M.B.A. Independent Director
Age: 51
Bio & Compensation  - Reuters
Michael Klein Independent Director
Age: 59
Bio & Compensation  - Reuters
Steven N. Rappaport Independent Director
Age: 64
Bio & Compensation  - Reuters
Somu Subramaniam Independent Director
Age: 58
Bio & Compensation  - Reuters